Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology recommended by NICE. These cookies remember information that ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] Technology appraisal guidance Venetoclax with ibrutinib for treating ...

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative devices and digital therapeutics transform patient care as ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

The lives of thousands of people with chronic kidney disease could be changed for the better after NICE today (Friday, 23 May) recommended a new treatment option for use in the NHS. Just over 4,200 ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

Somapacitan (Sogroya, Novo Nordisk) is indicated 'for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone ...